Johnson & Johnson (NYSE:JNJ) was downgraded by investment analysts at Vetr from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday. They currently have a $123.13 price target on the stock. Vetr‘s price objective suggests a potential upside of 3.55% from the company’s current price.

Several other research analysts also recently weighed in on the company. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday. Credit Suisse Group AG restated a “neutral” rating and issued a $123.00 price target on shares of Johnson & Johnson in a research note on Monday. Jefferies Group dropped their price target on Johnson & Johnson from $119.00 to $115.00 and set a “hold” rating for the company in a research note on Tuesday, September 13th. Leerink Swann restated a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, September 11th. Finally, BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $119.53.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.81% during midday trading on Wednesday, reaching $118.91. 6,337,292 shares of the company were exchanged. The company has a 50 day moving average price of $120.26 and a 200-day moving average price of $116.14. The stock has a market capitalization of $325.32 billion, a P/E ratio of 22.16 and a beta of 0.61. Johnson & Johnson has a 12-month low of $89.90 and a 12-month high of $126.07.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/johnson-johnson-jnj-rating-lowered-to-hold-at-vetr-inc-2.html

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.68 by $0.06. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. The business earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. On average, analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date was Friday, August 19th. Johnson & Johnson’s payout ratio is currently 60.15%.

In related news, CAO Ronald A. Kapusta sold 2,935 shares of the firm’s stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at $3,582,786.60. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the firm’s stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.

A number of large investors have recently modified their holdings of JNJ. Avalon Advisors LLC increased its stake in shares of Johnson & Johnson by 32.7% in the first quarter. Avalon Advisors LLC now owns 410,880 shares of the company’s stock worth $44,457,000 after buying an additional 101,250 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of Johnson & Johnson by 0.4% in the first quarter. Fisher Asset Management LLC now owns 10,854,263 shares of the company’s stock valued at $1,195,923,000 after buying an additional 38,299 shares in the last quarter. British Columbia Investment Management Corp increased its stake in shares of Johnson & Johnson by 1.0% in the second quarter. British Columbia Investment Management Corp now owns 1,649,232 shares of the company’s stock valued at $200,052,000 after buying an additional 17,000 shares in the last quarter. Legal & General Group Plc increased its stake in shares of Johnson & Johnson by 1.7% in the first quarter. Legal & General Group Plc now owns 13,449,262 shares of the company’s stock valued at $1,455,269,000 after buying an additional 226,357 shares in the last quarter. Finally, Investec Asset Management LTD increased its stake in shares of Johnson & Johnson by 49.2% in the first quarter. Investec Asset Management LTD now owns 5,050,411 shares of the company’s stock valued at $546,454,000 after buying an additional 1,665,644 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.